抗血小板药物“治疗无反应”的研究进展  

Research progress of antiplatelet drug "nonresponder"

作　　者：崔婵娟[1] 乔蕊[1] 张捷[1] 

机构地区：[1]北京大学第三医院检验科,北京100191

出　　处：《检验医学》2015年第12期1257-1262,共6页Laboratory Medicine

摘　　要：近年来新型抗血小板药物陆续出现,阿司匹林与氯吡格雷双联抗血小板仍是目前预防支架内血栓形成及不良心血管事件发生最常用药物。接受标准双联抗血小板药物治疗有部分患者仍再次发生临床缺血事件,出现抗血小板药物"治疗无反应"现象引起了人们极大关注。关于这一现象研究很多,这些研究都有一定局限性,如不同实验室检测体外血小板功能方法不同、不同患者对抗血小板药物反应存在广泛个体差异以及其他疾病对抗血小板药物疗效影响等。文章主要从体外检测血小板功能方法、药物代谢基因多态性及影响抗血小板药物代谢相关临床疾病等方面总结目前可能得到的证据,来阐述影响残余血小板活性原因及其与血栓形成事件之间关系。Despite the development of new antiplatelet agents,aspirin and clopidogrel dual antiplatelet therapy still has a major role in the prevention of stent thrombosis and ischemic events. However,a considerable number of patients in treatment with standard dual antiplatelet therapy continue to have cardiovascular events. This has been,in part,attributed to the fact that some patients may have poor antiplatelet effects. This phenomenon has caused considerable attention. Recently,a lot of researches on this phenomenon have appeared. However,these studies have some limitations,such as,the difference of platelet function tests,high inter-individual variability of antiplatelet agents and some other diseases affecting antiplatelet drug. In this review,we mainly discuss in vitro platelet function tests,genetic polymorphisms and some clinical disease interference with antiplatelet agents to elaborate the relationship between the reason of interference with antiplatelet agents and ischemic events.

关 键 词：抗血小板药物 治疗无反应 血小板活性 基因多肽性 

分 类 号：R446.11[医药卫生—诊断学]